SCHEMBL4737701

SCHEMBL4737701

O=C(O)CNC(=O)c1c(O)nc(-c2ccccc2)[nH]c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 2/20 0.48
FEN1 P39748 2/20 0.48
ERCC4 Q92889 2/20 0.48
RNASEH1 O60930 1/20 0.48
EGLN1 Q9GZT9 5/20 0.47
FTO Q9C0B1 2/20 0.47
KDM5B Q9UGL1 2/20 0.47
KDM2A Q9Y2K7 2/20 0.47
EGLN3 Q9H6Z9 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
KDM6B O15054 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
KDM3A Q9Y4C1 1/20 0.43
TNKS O95271 2/20 0.43
PARP1 P09874 2/20 0.43
TNKS2 Q9H2K2 2/20 0.43
USP2 O75604 1/20 0.43
TSHR P16473 1/20 0.43
MAPK1 P28482 1/20 0.43
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4737065 0.87 HPGD (0.46) ERCC1FEN1ERCC4RNASEH1EGLN1
SCHEMBL4997699 0.85 HSD17B10 (0.58) ERCC1FEN1ERCC4RNASEH1SMN1; SMN2
SCHEMBL4995190 0.83 EGLN3 (0.50) EGLN1FTOEGLN3
SCHEMBL10338070 0.77 ERCC1 (0.55) ERCC1FEN1ERCC4RNASEH1SMN1; SMN2
SCHEMBL3848693 0.71 ATM (0.44) EGLN1FTOKDM5BKDM2AEGLN3
SCHEMBL4740494 0.71 HTT (0.65) EGLN1FTOKDM5BKDM2AEGLN3
SCHEMBL3521291 0.71 EGLN3 (0.55) EGLN1FTOKDM5BKDM2AEGLN3
SCHEMBL821620 0.70 KMT2A (0.76) SMN1; SMN2USP2KDM4EALDH1A1LMNA
SCHEMBL2929993 0.70 MEN1 (0.50) EGLN1FTOKDM5BKDM2AEGLN3
SCHEMBL5304888 0.70 MEN1 (0.56) USP2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO claimed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US claimed
WO-2008089051-A1 N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2008-07-24 WO disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2008-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171756-A1 N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors HIF1AN, EGLN2, EGLN3 ERCC1 2651/4885FEN1 1331/4885ERCC4 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.